Order Article Reprints

Thieulent CJ, Sutton G, Toquet M-P, Fremaux S, Hue E, Fortier C, Pléau A, Deslis A, Abrioux S, Guitton E, et al. Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C₂₂₅₄ Variant. Pathogens. 2022; 11(5):539. https://doi.org/10.3390/pathogens11050539

Thieulent, Côme J., Gabrielle Sutton, Marie-Pierre Toquet, Samuel Fremaux, Erika Hue, Christine Fortier, Alexis Pléau, Alain Deslis, Stéphane Abrioux, Edouard Guitton, and et al. 2022. "Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C₂₂₅₄ Variant" Pathogens 11, no. 5: 539. https://doi.org/10.3390/pathogens11050539

Thieulent, C. J., Sutton, G., Toquet, M.-P., Fremaux, S., Hue, E., Fortier, C., Pléau, A., Deslis, A., Abrioux, S., Guitton, E., Pronost, S., & Paillot, R. (2022). Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C₂₂₅₄ Variant. Pathogens, 11(5), 539. https://doi.org/10.3390/pathogens11050539